JP6775422B2 - Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 - Google Patents
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 Download PDFInfo
- Publication number
- JP6775422B2 JP6775422B2 JP2016559176A JP2016559176A JP6775422B2 JP 6775422 B2 JP6775422 B2 JP 6775422B2 JP 2016559176 A JP2016559176 A JP 2016559176A JP 2016559176 A JP2016559176 A JP 2016559176A JP 6775422 B2 JP6775422 B2 JP 6775422B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence identification
- sequence
- identification number
- scfv
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972172P | 2014-03-28 | 2014-03-28 | |
| US61/972,172 | 2014-03-28 | ||
| US201462025974P | 2014-07-17 | 2014-07-17 | |
| US201462025931P | 2014-07-17 | 2014-07-17 | |
| US62/025,974 | 2014-07-17 | ||
| US62/025,931 | 2014-07-17 | ||
| PCT/US2015/023411 WO2015149077A1 (en) | 2014-03-28 | 2015-03-30 | Bispecific antibodies that bind to cd38 and cd3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020169262A Division JP7273016B2 (ja) | 2014-03-28 | 2020-10-06 | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511130A JP2017511130A (ja) | 2017-04-20 |
| JP2017511130A5 JP2017511130A5 (enExample) | 2018-05-24 |
| JP6775422B2 true JP6775422B2 (ja) | 2020-10-28 |
Family
ID=53053074
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559176A Active JP6775422B2 (ja) | 2014-03-28 | 2015-03-30 | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| JP2020169262A Active JP7273016B2 (ja) | 2014-03-28 | 2020-10-06 | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| JP2023012047A Pending JP2023052766A (ja) | 2014-03-28 | 2023-01-30 | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020169262A Active JP7273016B2 (ja) | 2014-03-28 | 2020-10-06 | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| JP2023012047A Pending JP2023052766A (ja) | 2014-03-28 | 2023-01-30 | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
Country Status (32)
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN105585630B (zh) | 2010-07-29 | 2020-09-15 | Xencor公司 | 具有修改的等电点的抗体 |
| SG190726A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Cytotoxicity-inducing therapeutic agent |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10968276B2 (en) * | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| TN2017000532A1 (en) | 2014-03-28 | 2019-04-12 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3. |
| WO2015156268A1 (ja) | 2014-04-07 | 2015-10-15 | 中外製薬株式会社 | 免疫活性化抗原結合分子 |
| CN106459954A (zh) | 2014-05-13 | 2017-02-22 | 中外制药株式会社 | 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN107406512A (zh) * | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| EA036156B1 (ru) * | 2015-05-08 | 2020-10-07 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| CN116675776A (zh) | 2015-10-25 | 2023-09-01 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
| JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| CN108699136B (zh) * | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| PL3411404T3 (pl) | 2016-02-03 | 2023-02-13 | Amgen Research (Munich) Gmbh | Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN109071667A (zh) * | 2016-03-08 | 2018-12-21 | 马弗里克治疗公司 | 可诱导性结合蛋白和使用方法 |
| EP3433273B1 (en) * | 2016-03-25 | 2021-12-29 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| CN109476732B (zh) * | 2016-04-13 | 2024-03-22 | 赛诺菲 | 三特异性和/或三价结合蛋白 |
| US10882914B2 (en) | 2016-04-15 | 2021-01-05 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
| AU2017255970B2 (en) | 2016-04-28 | 2024-06-27 | Biomunex Pharmaceuticals | Bispecific antibodies targeting EGFR and HER2 |
| WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| EP3464365A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
| EP3468586B1 (en) * | 2016-06-14 | 2024-08-07 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
| WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| CN109476763B (zh) * | 2016-07-19 | 2023-11-07 | 伊班绰斯有限责任公司 | 双特异性蛋白质及其制备方法 |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| KR20240044520A (ko) | 2016-09-14 | 2024-04-04 | 테네오원, 인코포레이티드 | Cd3 결합 항체 |
| US12188935B2 (en) | 2016-09-30 | 2025-01-07 | Centre National De La Recherche Scientifique | Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs |
| JP7083820B2 (ja) | 2016-09-30 | 2022-06-13 | セントレ ナショナル デ ラ レセルシュ シャンティフィク | 膜マーカー |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| EP4215548A1 (en) | 2016-12-21 | 2023-07-26 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| EP3575319A4 (en) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| CN108264562B (zh) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用 |
| AU2018220516B2 (en) * | 2017-02-16 | 2025-03-06 | Sonnet BioTherapeutics, Inc. | Albumin binding domain fusion proteins |
| SG11201908825TA (en) | 2017-03-27 | 2019-10-30 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| MX2019011769A (es) | 2017-04-03 | 2019-11-07 | Hoffmann La Roche | Anticuerpos que se unen a steap-1. |
| WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| US20200181274A1 (en) | 2017-06-01 | 2020-06-11 | Novartis Ag | Bispecific antibodies that bind cd 123 cd3 |
| NZ759835A (en) | 2017-06-08 | 2025-09-26 | Black Belt Therapeutics Ltd | Cd38 modulating antibody |
| US12343394B2 (en) | 2017-06-08 | 2025-07-01 | Black Belt Therapeutics Limited | CD38 modulating antibody agents |
| CN118146370A (zh) | 2017-06-20 | 2024-06-07 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| CN117866097A (zh) | 2017-06-20 | 2024-04-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111032693B (zh) | 2017-08-16 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CA3072296A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CA3075399A1 (en) * | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| JP7036909B2 (ja) | 2017-10-10 | 2022-03-15 | サノフイ | 抗ｃｄ３８抗体および使用方法 |
| WO2019079520A2 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2019094637A1 (en) * | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| SG11202005732XA (en) | 2017-12-19 | 2020-07-29 | Xencor Inc | Engineered il-2 fc fusion proteins |
| WO2019157340A1 (en) | 2018-02-08 | 2019-08-15 | Amgen Inc. | Low ph pharmaceutical antibody formulation |
| KR102900511B1 (ko) * | 2018-04-02 | 2025-12-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-trem-1 항체 및 이의 용도 |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
| CN112105645A (zh) | 2018-04-18 | 2020-12-18 | Xencor股份有限公司 | Il-15/il-15ra异二聚体fc融合蛋白及其用途 |
| WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| WO2019210147A1 (en) | 2018-04-27 | 2019-10-31 | Xencor, Inc. | Dosing of a bispecific antibody that bind cd123 and cd3 |
| WO2019224385A2 (en) * | 2018-05-24 | 2019-11-28 | Glenmark Pharmaceuticals S.A. | Combined bispecific antibody and immuno-oncology therapies |
| MX2020012797A (es) | 2018-06-01 | 2021-03-25 | Compugen Ltd | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. |
| PE20211091A1 (es) | 2018-07-02 | 2021-06-14 | Amgen Inc | Proteina de union al antigeno anti-steap1 |
| TW202019965A (zh) | 2018-07-16 | 2020-06-01 | 美商安進公司 | 治療多發性骨髓瘤之方法 |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| MX2021004147A (es) | 2018-10-09 | 2021-09-08 | Sanofi Sa | Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral. |
| MX2021004059A (es) | 2018-10-12 | 2021-09-23 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. |
| US20210388106A1 (en) * | 2018-10-26 | 2021-12-16 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| CA3122902A1 (en) | 2018-12-14 | 2020-06-18 | Morphosys Ag | Antibody formulations |
| WO2020132646A1 (en) | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| CA3131036A1 (en) * | 2019-02-22 | 2020-08-27 | Wuhan Yzy Biopharma Co., Ltd. | Cd3 antigen-binding fragment and application thereof |
| SG11202109406TA (en) | 2019-03-01 | 2021-09-29 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3 |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| WO2020205516A1 (en) | 2019-03-29 | 2020-10-08 | Xencor, Inc. | Dosing of a bispecific antibody that binds pd1 and ctla4 |
| PE20220142A1 (es) | 2019-04-05 | 2022-01-27 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| CA3141459A1 (en) | 2019-05-17 | 2020-11-26 | Xencor, Inc. | Il-7-fc-fusion proteins |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| EP3983438A1 (en) | 2019-06-14 | 2022-04-20 | TeneoBio, Inc. | Multispecific heavy chain antibodies binding to cd22 and cd3 |
| CN112111012B (zh) * | 2019-06-20 | 2023-07-04 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
| US20210102002A1 (en) | 2019-08-06 | 2021-04-08 | Xencor, Inc. | HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES |
| CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2021171264A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosing of a bispecific antibody that binds cd123 and cd3 |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| WO2021222595A2 (en) * | 2020-04-30 | 2021-11-04 | Virtuoso Binco, Inc. | Multispecific antibodies targeting cd38 and epcam and uses thereof |
| WO2021229306A2 (en) * | 2020-05-12 | 2021-11-18 | Virtuoso Binco,Inc. | Multispecific antibodies targeting cd38 and bcma and uses thereof |
| US20220106403A1 (en) | 2020-05-14 | 2022-04-07 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| BR112023002923A2 (pt) | 2020-08-24 | 2023-03-21 | Amgen Inc | Formulação farmacêutica que compreende um bite, anticorpo bespecífico, e metionina |
| US20220135684A1 (en) | 2020-10-14 | 2022-05-05 | Xencor, Inc. | Bispecific antibodies that bind pd-l1 and cd28 |
| WO2022087418A1 (en) | 2020-10-23 | 2022-04-28 | Xencor, Inc. | Anti-cd20 antibodies and therapeutic uses thereof |
| WO2022140701A1 (en) | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| MX2023011776A (es) * | 2021-04-05 | 2023-11-29 | Cytovia Therapeutics Llc | Anticuerpos biespecificos dirigidos a nkp46 y gpc3 y metodos de uso de los mismos. |
| JP2024523166A (ja) | 2021-06-15 | 2024-06-28 | ゼンコア インコーポレイテッド | クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体 |
| US20230146665A1 (en) | 2021-07-27 | 2023-05-11 | Xencor, Inc. | Il-18-fc fusion proteins |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
| CN115724985A (zh) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | 一种cdc平台抗体 |
| JP2024534620A (ja) | 2021-09-27 | 2024-09-20 | ゼンコア インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）結合ドメイン組成物 |
| WO2023081915A1 (en) | 2021-11-08 | 2023-05-11 | Xencor, Inc. | Il-8 as a predictive biomarker and methods of use thereof for the treatment of cancer |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| EP4482585A1 (en) | 2022-02-23 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| US20240025968A1 (en) | 2022-04-07 | 2024-01-25 | Xencor, Inc. | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20230383012A1 (en) | 2022-04-13 | 2023-11-30 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2, and/or cd28 |
| JP2025514115A (ja) | 2022-04-26 | 2025-05-02 | アムジエン・インコーポレーテツド | 凍結乾燥方法 |
| US12083189B2 (en) | 2022-04-29 | 2024-09-10 | Tiba Biotech, Llc | Tail-conjugated RNAs |
| WO2024102645A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| EP4665385A2 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| AU2024260531A1 (en) | 2023-04-28 | 2025-10-30 | Xencor, Inc. | Orthogonal multimeric proteins |
| AR133676A1 (es) | 2023-08-28 | 2025-10-22 | Xencor Inc | Combiterapia de anti-cd20 x anti-cd28 |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025085447A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Pd-1 targeted il18-fc fusion proteins |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025245508A1 (en) | 2024-05-24 | 2025-11-27 | Xencor, Inc. | Anti-tnf-like ligand 1a (tl1a) antibodies |
Family Cites Families (379)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| US4364935A (en) | 1979-12-04 | 1982-12-21 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human prothymocyte antigen and methods of preparing same |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| DE3783588T2 (de) | 1986-04-17 | 1993-06-09 | Kyowa Hakko Kogyo Kk | Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH05507080A (ja) | 1990-05-03 | 1993-10-14 | スクリップス クリニック アンド リサーチ ファウンデーション | カリキアマイシン及びエスペラマイシンオリゴサッカライドの形成用中間体 |
| US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
| CZ283717B6 (cs) | 1991-03-06 | 1998-06-17 | MERCK Patent Gesellschaft mit beschränkter Haftung | Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US6329507B1 (en) | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| WO1994013806A1 (en) | 1992-12-11 | 1994-06-23 | The Dow Chemical Company | Multivalent single chain antibodies |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ATE282630T1 (de) | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| EP0705833B1 (en) | 1994-04-22 | 2004-07-21 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivative |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7696338B2 (en) | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
| WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DK1049787T3 (da) | 1998-01-23 | 2005-04-04 | Vlaams Interuniv Inst Biotech | Antistofderivater med flere anvendelsesmuligheder |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| EP1089766B1 (en) | 1998-06-22 | 2010-03-17 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| US6716410B1 (en) | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| WO2001062931A2 (en) | 2000-02-25 | 2001-08-30 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US20010035606A1 (en) | 2000-03-28 | 2001-11-01 | Schoen Alan H. | Set of blocks for packing a cube |
| CA2407956A1 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20040091485A1 (en) | 2000-05-19 | 2004-05-13 | Ellis John Robert Maxwell | Humanised antibodies to the epidermal growth factor receptor |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| AU2001283496A1 (en) | 2000-07-25 | 2002-02-05 | Immunomedics, Inc. | Multivalent target binding protein |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20020147312A1 (en) | 2001-02-02 | 2002-10-10 | O'keefe Theresa | Hybrid antibodies and uses thereof |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| CA2442801A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with gntiii |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| IL154183A0 (en) | 2001-05-31 | 2003-07-31 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
| CA2452058A1 (en) | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| US6513428B1 (en) | 2001-07-23 | 2003-02-04 | Heidelberger Druckmaschinen Ag | Device and method for attaching a printing web to a webbing sail and device and method for webbing-up a printing machine |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| EP1490677A4 (en) | 2002-02-27 | 2006-01-18 | California Inst Of Techn | COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20080219974A1 (en) | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| WO2003100008A2 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| DE10246870B3 (de) | 2002-10-08 | 2004-04-29 | Renk Aktiengesellschaft | Elektro-Hydrodynamische Überlagerungslenkung |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| CA2505991C (en) | 2002-11-15 | 2018-02-27 | Genmab A/S | Human monoclonal antibodies against cd25 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| EP3524611B1 (en) | 2003-05-20 | 2020-12-30 | ImmunoGen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CN100509850C (zh) | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物 |
| CA2522894C (en) | 2003-05-31 | 2013-06-25 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| US7888134B2 (en) | 2003-06-05 | 2011-02-15 | Oakland University | Immunosensors: scFv-linker design for surface immobilization |
| US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| US7230068B2 (en) | 2003-10-09 | 2007-06-12 | Ambrx, Inc. | Polymer derivatives |
| US20050176028A1 (en) | 2003-10-16 | 2005-08-11 | Robert Hofmeister | Deimmunized binding molecules to CD3 |
| PL2489364T3 (pl) | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| US20050142133A1 (en) | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
| ATE554107T1 (de) | 2003-12-19 | 2012-05-15 | Genentech Inc | Als therapeutika geeignete monovalente antikörperfragmente |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| JP4889505B2 (ja) | 2004-02-02 | 2012-03-07 | アンブレツクス・インコーポレイテツド | 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用 |
| BRPI0507489A (pt) * | 2004-02-06 | 2007-07-10 | Morphosys Ag | anticorpos humanos de anti-cd38 e para os seus usos |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| CN1984931B (zh) * | 2004-06-03 | 2012-11-28 | 诺维莫尼公司 | 抗-cd3抗体及其使用方法 |
| US20060018897A1 (en) | 2004-06-28 | 2006-01-26 | Transtarget Inc. | Bispecific antibodies |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| US20060073142A1 (en) | 2004-09-02 | 2006-04-06 | Genentech, Inc. | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| CN101103045B (zh) | 2004-09-24 | 2015-11-25 | 安姆根有限公司 | 修饰的Fc分子 |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8066989B2 (en) | 2004-11-30 | 2011-11-29 | Trion Pharma Gmbh | Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy |
| DE602006003695D1 (de) | 2005-01-05 | 2009-01-02 | F Star Biotech Forsch & Entw | Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften |
| EP1847602B1 (en) | 2005-01-12 | 2014-04-23 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG2 ANTIBODIES |
| CA2603408C (en) | 2005-03-31 | 2018-08-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| BRPI0611765B1 (pt) | 2005-06-07 | 2022-09-27 | Esbatech Ag | Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica |
| CA2614181A1 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
| WO2007026252A2 (en) | 2005-07-01 | 2007-03-08 | Dako Denmark A/S | In situ hybridization detection method |
| CA2616386A1 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals Inc. | Single dose use of cd20-specific binding molecules |
| NZ606294A (en) | 2005-07-25 | 2014-09-26 | Emergent Product Dev Seattle | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070065437A1 (en) | 2005-09-12 | 2007-03-22 | Greg Elson | Anti-CD3 antibody formulations |
| CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
| SG10201400973XA (en) | 2005-10-12 | 2014-08-28 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| JP2009511067A (ja) | 2005-10-14 | 2009-03-19 | メディミューン，エルエルシー | 抗体ライブラリーの細胞提示 |
| WO2007047829A2 (en) | 2005-10-19 | 2007-04-26 | Laboratoires Serono S.A. | Novel heterodimeric proteins and uses thereof |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| WO2007062037A2 (en) | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| JP5374359B2 (ja) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| ES2654040T3 (es) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| CN101548034B (zh) | 2006-10-02 | 2013-11-13 | 航道生物技术有限责任公司 | 多样性合成肽和多肽文库的设计和构建 |
| ES2526292T3 (es) | 2006-10-16 | 2015-01-09 | The Salk Institute For Biological Studies | Antagonistas de la somatostatina selectivos para receptor (SSTR2) |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US7862825B2 (en) | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| US8114967B2 (en) | 2007-03-27 | 2012-02-14 | Sea Lane Biotechnologies Llc | Constructs and libraries comprising antibody surrogate light chain sequences |
| EP1975178A1 (en) | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| US20100150918A1 (en) | 2007-04-03 | 2010-06-17 | Micromet Ag | Cross-species-specific binding domain |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| AU2008260498B2 (en) | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| BRPI0812562A2 (pt) | 2007-06-12 | 2019-09-24 | Trubion Pharmaceuticals Inc | composições terapêuticas anti-cd20 e métodos |
| PL3241842T3 (pl) | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
| CA2695297C (en) | 2007-08-01 | 2017-03-21 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
| CA2695382A1 (en) | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| WO2009032782A2 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| EP2033657A1 (de) | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination |
| ES3006441T3 (en) | 2007-09-14 | 2025-03-18 | Amgen Inc | Homogeneous antibody populations |
| RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| ES2622460T3 (es) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| CA2703997C (en) | 2007-12-26 | 2017-04-04 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| WO2009106096A1 (en) | 2008-02-27 | 2009-09-03 | Fresenius Biotech Gmbh | Treatment of resistant tumors with trifunctional antibodies |
| MX340204B (es) | 2008-04-11 | 2016-06-30 | Emergent Product Dev Seattle | Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo. |
| US8314213B2 (en) | 2008-04-18 | 2012-11-20 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| WO2009135181A2 (en) | 2008-05-02 | 2009-11-05 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010028796A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
| ES2589852T3 (es) | 2008-09-17 | 2016-11-16 | Xencor Inc. | Anticuerpo específico para IgE |
| US20170247470A9 (en) | 2008-09-17 | 2017-08-31 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| KR20110047255A (ko) | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체 |
| WO2010037837A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| SG194399A1 (en) | 2008-10-01 | 2013-11-29 | Amgen Res Munich Gmbh | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| ME02485B (me) | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
| JP2012504970A (ja) | 2008-10-10 | 2012-03-01 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | Ｔｃｒ複合体免疫治療 |
| BRPI0921687A8 (pt) | 2008-11-03 | 2022-11-08 | Syntarga Bv | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. |
| EP2389192A4 (en) | 2009-01-23 | 2013-01-16 | Biogen Idec Inc | STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE |
| SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| AU2010230563A1 (en) | 2009-04-02 | 2011-09-22 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain Fab fragments |
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| EP2417164A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-2/anti-c-met antibodies |
| PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
| EP2241576A1 (en) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
| RU2570633C2 (ru) | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| EP2446032B8 (en) | 2009-06-26 | 2017-03-15 | i2 Pharmaceuticals, Inc. | Expression of surrogate light chains |
| MX2011013455A (es) | 2009-07-08 | 2012-02-13 | Amgen Inc | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| JP6092625B2 (ja) | 2009-10-27 | 2017-03-08 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | ＣＤ１９ｘＣＤ３二重特異性抗体を投与するための投与計画 |
| US9200060B2 (en) | 2009-11-23 | 2015-12-01 | Amgen Inc. | Monomeric antibody Fc |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| JP5784624B2 (ja) | 2009-11-30 | 2015-09-24 | ヤンセン バイオテツク，インコーポレーテツド | 除去されたエフェクター機能を伴う抗体Ｆｃ突然変異 |
| US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
| KR102103093B1 (ko) | 2009-12-25 | 2020-04-21 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US20110189178A1 (en) | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
| AU2011235569B2 (en) | 2010-03-29 | 2016-06-30 | Zymeworks Bc Inc. | Antibodies with enhanced or suppressed effector function |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| PT2580243T (pt) | 2010-06-09 | 2020-01-22 | Genmab As | Anticorpos contra cd38 humana |
| CN105585630B (zh) | 2010-07-29 | 2020-09-15 | Xencor公司 | 具有修改的等电点的抗体 |
| EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| UA113397C2 (xx) | 2010-11-10 | 2017-01-25 | Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3 | |
| WO2012065055A2 (en) | 2010-11-12 | 2012-05-18 | The Rockefeller University | Fusion proteins for hiv therapy |
| TWI666027B (zh) | 2011-02-10 | 2019-07-21 | 羅齊克雷雅公司 | 突變介白素-２多肽 |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| CA2829628A1 (en) | 2011-03-11 | 2012-09-20 | Amgen Inc. | Method of correlated mutational analysis to improve therapeutic antibodies |
| ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
| BR112013023918A2 (pt) * | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| BR112013024574B1 (pt) | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| KR102345943B1 (ko) | 2011-04-28 | 2021-12-31 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| UA115402C2 (uk) | 2011-05-21 | 2017-10-25 | Макродженікс, Інк. | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським |
| KR20140028013A (ko) | 2011-05-25 | 2014-03-07 | 머크 샤프 앤드 돔 코포레이션 | 개선된 특성을 갖는 Fc-함유 폴리펩티드를 제조하는 방법 |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
| TR201802089T4 (tr) | 2011-08-04 | 2018-03-21 | Toray Industries | Kanserin tedavisi ve/veya önlenmesi amacına yönelik ilaç bileşimi. |
| WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
| CA2845391C (en) | 2011-08-18 | 2021-01-19 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
| RS56879B1 (sr) | 2011-08-23 | 2018-04-30 | Roche Glycart Ag | Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| JP6310394B2 (ja) | 2011-10-10 | 2018-04-11 | ゼンコア インコーポレイテッド | 抗体を精製する方法 |
| CN109608543A (zh) | 2011-10-20 | 2019-04-12 | 艾斯巴技术-诺华有限责任公司 | 稳定的多抗原结合抗体 |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| KR102398736B1 (ko) | 2011-10-31 | 2022-05-16 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
| HRP20211773T1 (hr) | 2011-11-04 | 2022-03-04 | Zymeworks Inc. | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni |
| US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| US9975956B2 (en) | 2011-12-22 | 2018-05-22 | I2 Pharmaceuticals, Inc. | Surrogate binding proteins which bind DR4 and/or DR5 |
| KR20250007041A (ko) | 2012-02-24 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자 |
| CA2870821C (en) | 2012-04-20 | 2022-06-14 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CA3212759A1 (en) | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| ES2856272T3 (es) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| IN2015DN01299A (enExample) | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| IN2015MN00139A (enExample) | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
| KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US9951145B2 (en) | 2012-11-27 | 2018-04-24 | Ajou University Industry—Academic Cooperation Foundation | CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| WO2014100490A1 (en) | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9701759B2 (en) * | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| CN103943548A (zh) | 2013-01-23 | 2014-07-23 | 无锡华润上华半导体有限公司 | 分立式场氧结构的半导体器件的制造方法 |
| US20140271462A1 (en) | 2013-03-13 | 2014-09-18 | Imaginab, Inc. | Antigen binding constructs to cd8 |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP2951203B1 (en) | 2013-03-15 | 2019-05-22 | Xencor, Inc. | Heterodimeric proteins |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| GB201311487D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| DK3444271T3 (da) | 2013-08-08 | 2022-01-10 | Cytune Pharma | Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| CN105873953A (zh) * | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| JP6449295B2 (ja) | 2013-12-17 | 2019-01-09 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体および使用方法 |
| KR20160099092A (ko) | 2013-12-17 | 2016-08-19 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
| JP6706578B2 (ja) | 2013-12-30 | 2020-06-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリン及びその使用 |
| AU2014377106B2 (en) | 2014-01-08 | 2019-10-03 | Jiangsu Hengrui Medicine Co., Ltd. | IL-15 heterodimeric protein and uses thereof |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TN2017000532A1 (en) | 2014-03-28 | 2019-04-12 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3. |
| US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| PE20170765A1 (es) | 2014-05-29 | 2017-07-04 | Macrogenics Inc | Moleculas de union tri-especificas y metodos de uso de las mismas |
| CA2956178A1 (en) | 2014-07-24 | 2016-01-28 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| EP3221355B1 (en) | 2014-11-20 | 2020-10-07 | F.Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| CN107406512A (zh) * | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| US10259887B2 (en) * | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| CN109476761B (zh) | 2015-01-08 | 2020-01-10 | 生物技术公司 | 激动性tnf受体结合剂 |
| JP2018503399A (ja) | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| EA036156B1 (ru) | 2015-05-08 | 2020-10-07 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены |
| FI3313441T3 (fi) | 2015-06-24 | 2024-03-28 | Janssen Biotech Inc | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| US20180305465A1 (en) * | 2015-11-25 | 2018-10-25 | Amgen Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| KR20180089444A (ko) | 2015-12-22 | 2018-08-08 | 리제너론 파아마슈티컬스, 인크. | 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합 |
| WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| EP3464365A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| RU2018145961A (ru) | 2016-06-07 | 2020-07-14 | Макродженикс, Инк. | Комбинированная терапия |
| EP3468586B1 (en) | 2016-06-14 | 2024-08-07 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| TW201815825A (zh) | 2016-07-21 | 2018-05-01 | 財團法人生物技術開發中心 | 經修飾之抗原結合fab片段及包含其之抗原結合分子 |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
| US20210061911A1 (en) | 2017-09-07 | 2021-03-04 | Macrogenics, Inc. | Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| US20210102002A1 (en) | 2019-08-06 | 2021-04-08 | Xencor, Inc. | HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES |
-
2015
- 2015-03-30 TN TNP/2017/000532A patent/TN2017000532A1/en unknown
- 2015-03-30 CR CR20160506A patent/CR20160506A/es unknown
- 2015-03-30 PL PL15720820T patent/PL3122781T3/pl unknown
- 2015-03-30 MX MX2016012578A patent/MX385936B/es unknown
- 2015-03-30 LT LTEP15720820.8T patent/LT3122781T/lt unknown
- 2015-03-30 ES ES15720820T patent/ES2775431T3/es active Active
- 2015-03-30 JP JP2016559176A patent/JP6775422B2/ja active Active
- 2015-03-30 EP EP21172032.1A patent/EP3954713A3/en active Pending
- 2015-03-30 BR BR112016022385-3A patent/BR112016022385A2/pt not_active Application Discontinuation
- 2015-03-30 SI SI201531079T patent/SI3122781T1/sl unknown
- 2015-03-30 SM SM20200141T patent/SMT202000141T1/it unknown
- 2015-03-30 KR KR1020167029551A patent/KR102327996B1/ko active Active
- 2015-03-30 KR KR1020217023950A patent/KR102497443B1/ko active Active
- 2015-03-30 EA EA201691925A patent/EA201691925A1/ru unknown
- 2015-03-30 PT PT157208208T patent/PT3122781T/pt unknown
- 2015-03-30 AU AU2015237184A patent/AU2015237184B2/en not_active Ceased
- 2015-03-30 CA CA2943621A patent/CA2943621A1/en active Pending
- 2015-03-30 IL IL248007A patent/IL248007B/en unknown
- 2015-03-30 EP EP15720820.8A patent/EP3122781B1/en active Active
- 2015-03-30 HU HUE15720820A patent/HUE048734T2/hu unknown
- 2015-03-30 SG SG11201607983YA patent/SG11201607983YA/en unknown
- 2015-03-30 UA UAA201610778A patent/UA119167C2/uk unknown
- 2015-03-30 CN CN201911247777.7A patent/CN111410691B/zh active Active
- 2015-03-30 SG SG10202008629XA patent/SG10202008629XA/en unknown
- 2015-03-30 WO PCT/US2015/023411 patent/WO2015149077A1/en not_active Ceased
- 2015-03-30 KR KR1020237004018A patent/KR20230022270A/ko not_active Ceased
- 2015-03-30 HR HRP20200164TT patent/HRP20200164T1/hr unknown
- 2015-03-30 AP AP2016009475A patent/AP2016009475A0/en unknown
- 2015-03-30 DK DK15720820.8T patent/DK3122781T3/da active
- 2015-03-30 ME MEP-2020-43A patent/ME03666B/me unknown
- 2015-03-30 RS RS20200150A patent/RS59907B1/sr unknown
- 2015-03-30 US US14/673,695 patent/US9822186B2/en active Active
- 2015-03-30 PE PE2016001729A patent/PE20161431A1/es unknown
- 2015-03-30 CN CN201580016659.9A patent/CN106471009B/zh active Active
- 2015-03-30 EP EP19213494.8A patent/EP3699195A3/en not_active Withdrawn
-
2016
- 2016-09-27 MX MX2021010413A patent/MX2021010413A/es unknown
- 2016-09-27 PH PH12016501908A patent/PH12016501908A1/en unknown
- 2016-09-28 CL CL2016002460A patent/CL2016002460A1/es unknown
-
2017
- 2017-10-17 US US15/786,252 patent/US10858451B2/en active Active
-
2020
- 2020-03-06 CY CY20201100205T patent/CY1123236T1/el unknown
- 2020-10-06 JP JP2020169262A patent/JP7273016B2/ja active Active
- 2020-10-30 US US17/086,213 patent/US11840579B2/en active Active
-
2021
- 2021-02-25 AU AU2021201249A patent/AU2021201249A1/en not_active Abandoned
-
2023
- 2023-01-30 JP JP2023012047A patent/JP2023052766A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7273016B2 (ja) | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 | |
| US10519242B2 (en) | Targeting regulatory T cells with heterodimeric proteins | |
| US20250154281A1 (en) | Anti-steap1 antigen-binding protein | |
| CN110981964A (zh) | 新型异二聚体蛋白 | |
| CN111138543A (zh) | 异二聚体蛋白 | |
| HK40027796A (en) | Novel heterodimeric proteins | |
| HK40026815A (en) | Heterodimeric proteins | |
| HK1227894B (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| HK1227894A1 (en) | Bispecific antibodies that bind to cd38 and cd3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190301 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200430 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201006 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6775422 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |